Vir Biotechnology's Hepatitis Delta therapy shows strong Phase 3 results, securing a Buy rating and partnership with Gilead.

Vir Biotechnology reported successful Phase 3 ECLIPSE 1 trial results for its Hepatitis Delta therapy, achieving 44% primary endpoint success and 79% undetectable virus rates with a strong safety profile. The company also secured a major partnership with Gilead and holds nearly $1 billion in cash, providing financial stability through mid-2028. These factors support a Buy rating with a risk-adjusted fair value estimate of $15.48 per share, above current trading levels, indicating limited downside risk and potential for growth.

Vir Biotechnology shares are trading at USD 13.69 on Pluang, showing a slight increase of 0.33% as of Nov 10, 2026 20:32 WIB. The stock sees balanced order activity with 51% buying and 49% selling interest at this time.